FBRX - Forte Biosciences, Inc.

28.86
-0.970   -3.361%

Share volume: 228,647
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$29.83
-0.97
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 22%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-16.18%
1 Month
12.21%
3 Months
-11.31%
6 Months
138.32%
1 Year
314.66%
2 Year
3,908.89%
Key data
Stock price
$28.86
P/E Ratio 
0.00
DAY RANGE
$28.07 - $30.55
EPS 
-$4.41
52 WEEK RANGE
$6.13 - $35.80
52 WEEK CHANGE
$330.31
MARKET CAP 
186.493 M
YIELD 
N/A
SHARES OUTSTANDING 
35.588 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$248,777
AVERAGE 30 VOLUME 
$428,518
Company detail
CEO: Paul A. Wagner
Region: US
Website: fortebiorx.com
Employees: 5
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Forte Biosciences is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Recent news